Lilly deploys obesity cash into $3.8B vaccine buying spree
Eli Lilly (NYSE:LLY) announced an aggressive expansion into the infectious disease prevention sector, entering into definitive agreements to acquire three distinct vaccine developers for a combined potential value of up to $3.83 billion in cash.


_1406754_640x360_2501328963682-640x360.webp&w=3840&q=75)

_1406721_640x360_2501327939604-640x360.webp&w=3840&q=75)



_1406691_640x360_2501325891686-640x360.webp&w=3840&q=75)
